Inhibikase Therapeutics, Inc. dismissed CohnReznick LLP as its independent registered public accounting firm effective August 21, 2026, and appointed Deloitte & Touche LLP to replace them for the fiscal year ending December 31, 2026. The company confirmed that audit reports from CohnReznick for fiscal years ended December 31, 2025, and 2024 contained no adverse opinions or qualifications. There were no disagreements between the company and CohnReznick regarding accounting principles, financial statement disclosures, or auditing scope. A material weakness in internal control over financial reporting was previously disclosed for the quarter ended June 30, 2024, but had been remediated by September 30, 2024. The filing includes a letter from CohnReznick dated August 26, 2026. Inhibikase Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare genetic diseases.

Inhibikase Therapeutics reported a net loss of $19.6 million ($0.11 per share) for the quarter ended June 30, 2026, compared to a $9.9 million loss in the prior year period. Cash and marketable securities totaled $159.0 million as of June 30, with an additional $50 million raised in July through the sale of 25 million shares to RA Capital Management via its at-the-market facility. The company advanced its Phase 3 IMPROVE-PAH study for IKT-001, securing regulatory approvals in 26 countries and initiating 43 clinical sites. Additionally, the FDA granted Orphan Drug Designation for IKT-001. Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension.

On July 29, 2026, Inhibikase Therapeutics entered into an exchange agreement with RA Capital Healthcare Fund to swap 18,030,000 shares of common stock for a pre-funded warrant. The warrant carries a $0.001 exercise price, is immediately exercisable, and has no expiration date. It includes a beneficial ownership blocker limiting holdings to 9.99% of outstanding shares, adjustable with notice up to 19.99%. This transaction was executed under Section 3(a)(9) of the Securities Act exemption. Inhibikase Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

On July 23, 2026, Inhibikase Therapeutics announced that the FDA granted Orphan Drug Designation (ODD) to its lead product candidate, IKT-001, for the treatment of Pulmonary Arterial Hypertension (PAH). The ODD applies to the active moiety, imatinib, and provides incentives including tax credits for clinical trial costs, exemption from certain FDA user fees, and potential seven-year market exclusivity upon approval. IKT-001 is currently in a pivotal Phase 3 clinical study named IMPROVE-PAH, which is actively enrolling patients across approximately 180 global sites. The company is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases.